Status:
UNKNOWN
Impact of Erythropoietin Administration During Definitive Cervix Cancer Radiotherapy on Treatment Outcome
Lead Sponsor:
Medical University of Vienna
Conditions:
Cervix Cancer
Eligibility:
FEMALE
19-80 years
Phase:
PHASE3
Brief Summary
The purpose of this study is to determine whether an increase of blood haemoglobin levels through the substitution of erythropoietin during radiotherapy treatment of cervix cancer patients results in ...
Detailed Description
Definitive radiotherapy is the treatment of choice for patients with locally advanced cervix cancer. Low pre-therapeutic values of the intratumoral pO2 are associated with significantly worse therapeu...
Eligibility Criteria
Inclusion
- histologically proven cervix cancer (FIGO stage I-IVA)
- Age of 19-80 years
- initial blood level of hemoglobin \<= 14 g/dl
- patients who gave their informed consent
Exclusion
- Karnofsky-Index \< 50 %
- known intolerance of erythropoietin
- FIGO stage IVB
- blood transfusion within the last four weeks
- neoadjuvant chemotherapy
- previous radiation therapy of the abdomen
Key Trial Info
Start Date :
July 1 2000
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
July 1 2009
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00348738
Start Date
July 1 2000
End Date
July 1 2009
Last Update
November 2 2007
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Radiotherapy-University Hospital of Innsbruck
Innsbruck, Austria, A-6020
2
Department of Radiotherapy-University Hospital of Salzburg
Salzburg, Austria, A-5020
3
Department of Radiotherapy and Radiobiology-Medical University of Vienna
Vienna, Austria, A-1090
4
Department of Radiotherapy-Hospital of Hietzing
Vienna, Austria, A-1130